BioSpace News Archive

CURE debuts “CUREinside” quality mark on the packaging of ReLeaf Europe’s sublingual tinctures and new topical cream product lines

GE Healthcare Life Sciences and Children’s Medical Research Institute will jointly drive the development of new affinity ligands for the purification of adeno-associated viral (AAV), vectors used in gene therapies

Beam Therapeutics Inc. announced the pricing of its initial public offering of 10,588,236 shares of common stock at a public offering price of $17.00 per share.

Cortexyme, Inc. announced that it has entered into stock purchase agreements with a group of institutional investors and an entity affiliated with a member of the Company’s Board of Directors in connection with a private placement of its common stock.

Schrödinger, Inc. announced the pricing of its initial public offering of 11,882,352 shares of common stock at a public offering price of $17.00 per share, for total gross proceeds of approximately $202.0 million, before underwriting discounts and commissions and offering expenses payable by the Company.

Horizon Discovery Group plc (LSE: HZD) (“Horizon” “the Group” or “the Company”), a global leader in the application of gene editing and gene modulation technologies, today provides an unaudited pre-close trading update for the year ended 31 December 2019.

Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatment, today reported preliminary gross sales of $7.8 million for the fourth quarter ended December 31, 2019 representing an 11.4% increase over gross sales of $7.0 million for the third quarter ended September 30, 2019 based on total boxes shipped.

Diomics Corporation, a leader in forensic, diagnostic, and therapeutic science since 2009, today announced that it has developed intellectual property and patents related to the identification of airborne pathogens.

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of serlopitant for the treatment of pruritus associated with psoriasis in the Journal of the American Academy of Dermatology (JAAD).

Company positioned for continued growth in health care, life sciences, human resources/employer, and legal conferences.